45 results about "Angiotensinamide" patented technology

Disclosed are compositions containing a VDRA / Vitamin D analog to treat or prevent kidney disease, including chronic kidney disease. The present invention also relates to methods of treating kidney disease by administering to a patient a pharmaceutical composition containing a therapeutically effective amount of a VDRA / Vitamin D analog. Compositions according to the invention include a VDRA / Vitamin D analog and at least one of the following agents: an ACE inhibitor, an angiotensin (II) receptor blocker (ARB) and aldosterone blocker in therapeutically effective amounts to inhibit renin production or inhibit activation of the renin-angiotensin-aldosterone system. Preferred compositions contain paricalcitol with at least one of these other agents. Such combinations can avoid ACE inhibition escape and aldosterone escape with subsequent increase in angiotensin (II) and aldosterone generation.

Disclosed are compositions containing a VDRA / Vitamin D analog to treat or prevent kidney disease, including chronic kidney disease. The present invention also relates to methods of treating kidney disease by administering to a patient a pharmaceutical composition containing a therapeutically effective amount of a VDRA / Vitamin D analog. Compositions according to the invention include a VDRA / Vitamin D analog and at least one of the following agents: an ACE inhibitor, an angiotensin (II) receptor blocker (ARB) and aldosterone blocker in therapeutically effective amounts to inhibit renin production or inhibit activation of the renin-angiotensin-aldosterone system. Preferred compositions contain paricalcitol with at least one of these other agents. Such combinations can avoid ACE inhibition escape and aldosterone escape with subsequent increase in angiotensin (II) and aldosterone generation.

The invention discloses a one-step method based solid-phase polypeptide synthesis method. The technology of blowing in nitrogen or insert gases to volatilize a volatile solvent and reduce the temperature is adopted in each condensation reaction of connected protected amino acids, the nitrogen or the insert gases are filled into a reaction mixture so that the volatile solvent is volatilized and the temperature of a reaction system can be maintained at 15-20 DEG C, after an auxiliary condensing agent is added to start the condensation reaction, the temperature of the condensation reaction system is always stabilized at 22-28 DEG C by a heat insulation device, and during condensation of protected amino acids, the amino acids are unnecessary to be activated at low temperature in an activator and then be transferred to a condensation reactor, thus all the chemical reactions for synthesizing polypeptide are continuously completed in the same reactor in sequence. The method for synthesizing angiotensinamide is environment-friendly and efficient, has low requirements for equipment and can be applied to large-scale industrial production.

The present invention provides conjugates of peptide derivatives of the mammalian peptide hormones angiotensinogen, angiotensin I and angiotensin II, presented in a repetitive scaffold by coupling the peptide derivatives to a carrier, particularly a virus-like particle (VLP). The invention also provides methods of producing such conjugates, and immunotherapeutic uses of the resulting immunogen conjugates for the therapy and prophylaxis of conditions associated with the renin-activated angiotensin system.

Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.

Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.

Disclosed herein is a combination therapy and a combination preparation of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor characterized in that the angiotensin-II-receptor blocker is absorbed substantially later than the HMG-CoA reductase inhibitor. As the angiotensin-II-receptor blocker and the HMG-CoA reductase inhibitor are released at different times, the present combination therapy prevents competitive inhibition between the two drugs and side effects, as well as simultaneously provides synergistic effects for each active ingredient and convenience of taking the drugs.

The prior art lacks a formulation, application or product of D-Ala7-Angiotensin-(1-7) (A-779) and analogues and derivatives, D-Pro7-Angiotensin-(1-7) and analogues or derivatives or of Ang-(1-7) analogues or derivatives using ciclodextrines, lipossomes, biodegradable polymers and its derivatives for the study or treatment of arterial hypertension and other cardiovascular diseases, wounds, burns, erithema, tumors, diabetes mellitus, sperm mobility, nephropathy, gastrointestinal and gynaecological disorders, angiogenesis, angioplatsy, alopecia and blood diseases in warm blooded animals, or as ligands for de G-protein-coupled receptor MAS. This characterizes the present invention as a more effective option for the study and treatment of pathologies associated or not to this receptor. A combination of two different technologies are provided: the molecular encapsulament of the peptide angiotensin-(1-7) and its analogues and derivates in cyclodextrin and the microencapsulament in biodegradable polymers and lipossomes. It is also characterized by the increase of this peptides and its analogues and derivatives using the formulation.

The invention relates to 3-pyrrole carboxylic acid derivatives, and a preparing method and an application thereof, and particularly relates to the 3-pyrrole carboxylic acid derivatives having a structure represented by formula I and pharmaceutically acceptable salts thereof and the preparing method of the derivatives, pharmaceutical compositions with the 3-pyrrole carboxylic acid derivatives having the structure represented by the formula I and the pharmaceutically acceptable salts of the 3-pyrrole carboxylic acid derivatives as active ingredients, and applications of the pharmaceutical compositions in prevention or treatment of diseases related with an arginine vasopressin V1a receptor, an arginine vasopressin V1b receptor, an arginine vasopressin V2 receptor, a sympathetic nervous system or a renin-angiotensin-aldosterone system.

The invention relates to desloratadine derivatives, and a preparation method and application thereof, particularly desloratadine derivatives disclosed as Formula I and pharmaceutically acceptable salts thereof and a preparation method thereof, and application of the desloratadine derivatives disclosed as Formula I and pharmaceutically acceptable salts thereof as active effective ingredients of active pharmaceutical compositions in preventing and treating diseases related to arginine vasopressin V1a receptor, arginine vasopressin V1b receptor, arginine vasopressin V2 receptor, sympathetic nervous system or renin-angiotensin-aldosterone system.

The invention relates to a drug composition. The drug composition consists of an effective treating amount of calcium antagonist (CCB), an angiotensin II receptor blocker (ARB), a thiazide diuretic, a folic acid compound and a pharmaceutically acceptable carrier, wherein the content of the CCB is 2-240 mg, the content of the ARB is 4-600 mg, the content of the thiazide diuretic is 0.625-25 mg, and the content of the folic acid compound is 0.4-0.4 mg. The drug composition has the advantages that the drug composition can effectively improve the treatment effect of reducing blood pressure of class-2 and class-3 hypertensive patients, strengthen the effect of protecting target organs of the patients and reduce the occurrence risk of cerebral apoplexy complications caused by high blood pressure. In addition, the drug composition can be conveniently taken by patients, the treatment compliance is greatly improved, and the medical costs can be also reduced.

A process for the preparation of angiotensin II antagonists and novel intermediates useful for the synthesis thereof.

The present invention provides (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-cyclopropyl-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate represented by the formula: which has superior properties as a pharmaceutical agent, a salt thereof, a crystal thereof, a pharmaceutical agent containing the compound, and the like.

The invention relates to a sulfonamide compound, and a preparation method and application thereof. Particularly, the invention relates to the sulfonamide compound with a structure shown in the formula I, an acceptable salt of the sulfonamide compound on the pharmacy, and a preparation method of the sulfonamide compound. A medicine composition uses the sulfonamide compound with the structure shown in the formula I, and the acceptable salt of the sulfonamide compound on the pharmacy as active ingredients to be used for preventing or treating diseases related to arginine vasopressin V1a receptors, arginine vasopressin V1b receptors, arginine vasopressin V2 receptors, a sympathetic nervous system or a renin-angiotensin-aldosterone system.

Disclosed herein is a combination therapy and a combination preparation of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor characterized in that the angiotensin-II-receptor blocker is absorbed substantially later than the HMG-CoA reductase inhibitor. As the angiotensin-II-receptor blocker and the HMG-CoA reductase inhibitor are released at different times, the present combination therapy prevents competitive inhibition between the two drugs and side effects, as well as simultaneously provides synergistic effects for each active ingredient and convenience of taking the drugs.

The invention relates to analogs of angiotensins, in particular to cyclised analogs having Ang(1-8) agonistic or antagonistic activity and to cyclised Ang(1-7) analogs with agonistic or antagonistic activity and displaying improved proteolytic resistance compared to their linear counterparts. Provided is a cyclic angiotensin peptide analog comprising a thioether-bridge linkage between the amino acids corresponding to positions Tyr4 and Pro7 in naturally occurring Angiotensin. Also provided is the use of analogs in therapy, for example hypertension.

The invention relates to bisulfamide compounds as well as a preparation method and use thereof, and specifically relates to bisulfamide compounds having the structure as shown in a formula I and pharmaceutically acceptable salts thereof as well as a preparation method of the bisulfamide compounds, pharmaceutical compositions with the bisulfamide compounds having the structure as shown in the formula I and the pharmaceutically acceptable salts thereof as active effective constituents and use of the pharmaceutical compositions in preventing or treating diseases associated with an arginine vasopressin V1a receptor, an arginine vasopressin V1b receptor, an arginine vasopressin V2 receptor, the sympathetic nervous system or the renin-angiotensin-aldosterone system; the formula I is as shown in the specification.

A method of treatment of indications which can be positively influenced by inhibition of AT1 mediated effects with maintenance of AT2 receptor mediated effects of angiotensin II and by ACE inhibition, thus also increasing bradykinin mediated effects, e.g., to reduce the incidence of stroke, acute myocardial infarction or cardiovascular death, or of indications associated with the increase of AT1 receptors in the subepithelial area or increase of AT2 receptors in the epithelia, comprising coadministration of effective amounts of an angiotensin II antagonist and an ACE inhibitor, pharmaceutical compositions containing an angiotensin II antagonist together with an ACE inhibitor and the use of an angiotensin II antagonist and an ACE inhibitor for the manufacture of corresponding pharmaceutical compositions.

The invention relates to compounds with two amido bonds as well as a preparation method and use of the compounds, and particularly relates to compounds with two amido bonds having structures as shown in the formula I, pharmaceutically acceptable salts of the compounds, preparation methods of the pharmaceutically acceptable salts and the compounds, a pharmaceutical composition of the compounds with the two amido bonds having the structures as shown in the formula I and the pharmaceutically acceptable salts as effective components, and use of the pharmaceutical composition in prevention or treatment of diseases related to an arginine vasopressin V1a receptor, an arginine vasopressin V1b receptor, an arginine vasopressin V2 receptor, a sympathetic nervous system or a rennin-angiotensin-aldosterone system.

The invention relates to N-substituted benzoyl phenothiazine compounds as well as a preparation method and application thereof, and particularly relates to N-substituted benzoyl phenothiazine compounds having a structure as shown in a formula I described in the specification as well as a preparation method of the compounds, pharmaceutical compositions taking the N-substituted benzoyl phenothiazine compounds having a structure as shown in the formula I as active ingredients and use of the pharmaceutical compositions for preventing or treating diseases related to an arginine vasopressin V1a receptor, an arginine vasopressin V1b receptor, an arginine vasopressin V2 receptor, a sympathetic nervous system or a rennin-angiotensin-aldosterone system.

The invention relates to a phosphate ester-containing piperazine derivative and a preparation method as well as application thereof, in particular to one type of phosphate ester-containing piperazine derivatives with a structure shown by a formula I and a preparation method thereof, a medicinal composition with the phosphate ester-containing piperazine derivative with the structure shown by the formula I as an active ingredient and application thereof to preventing or treating diseases related to arginine vasopressin V1a receptors, arginine vasopressin V1b receptors, arginine vasopressin V2 receptors, a sympathetic nervous system or a renin-angiotensin-aldosterone system.

The present invention relates to a pharmaceutical composition comprising a. at least one aspartyl aminopeptidase inhibitor and at least one angiotensin-converting-enzyme (ACE) inhibitor, or b. at least one aspartyl aminopeptidase inhibitor and at least one chymase inhibitor. In an embodiment, the pharmaceutical composition comprises at least one aspartyl aminopeptidase inhibitor and at least one angiotensin-converting-enzyme (ACE) inhibitor and at least one chymase inhibitor. Furthermore, the invention relates to a pharmaceutical composition possessing inhibitory activity against a. aspartyl aminopeptidase and angiotensin-converting-enzyme (ACE), or b. against aspartyl aminopeptidase and chymase. In a third aspect, the invention relates to a kit of parts comprising a. a pharmaceutical composition comprising an aspartyl aminopeptidase inhibitor and a pharmaceutical composition comprising an angiotensin-converting-enzyme (ACE) inhibitor, or b. a pharmaceutical composition comprising an aspartyl aminopeptidase inhibitor and a pharmaceutical composition comprising a chymase inhibitor, or c. a pharmaceutical composition comprising an aspartyl aminopeptidase inhibitor and a pharmaceutical composition comprising an angiotensin-converting-enzyme (ACE) inhibitor and a pharmaceutical composition comprising a chymase inhibitor. The invention also relates to a method for decreasing the blood pressure in a subject by administering a therapeutically effective amount of a pharmaceutical composition according to the invention to the subject. In another aspect, the invention relates to a method for treating a disease related to the RAS in a subject by administering a therapeutically effective amount of a pharmaceutical composition according to the invention to the subject.

The present invention relates to certain pharmaceutical compositions containing at least one vasopressin receptor antagonist and at least one angiotensin receptor blocker (ARB) and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of vasopressin and / or angiotensin-mediated disorders.

The invention provides a pharmaceutical composition for treating hypertension. The pharmaceutical composition is characterized by comprising (1) angiotensin II receptor blocker, (2) diuretic metolazone, (3) calcium channel blocker and (4) pharmaceutically acceptable adjuvant materials, wherein the weight ratio among the angiotensin receptor blocker, the metolazone and the calcium channel blocker is 2-200:0.5-5:2-50. The pharmaceutical composition for treating hypertension has the advantages that the pharmaceutical composition combines the angiotensin receptor blocker, the metolazone and the calcium channel blocker, and accordingly, synergetic antihypertensive effect is enhanced, adverse reaction is reduced and compliance of patients is improved; the pharmaceutical composition is wide in application range and can be also used for patients suffering from severe renal damage; the pharmaceutical composition is applicable to mild and moderate essential hypertension, particularly secondary hypertension caused by renal damage.

The invention relates to a disulfamide phenothiazine compound, and a preparation method and an application thereof, and particularly relates to the disulfamide phenothiazine compound with a structure of a formula I shown in the specification and the preparation method thereof, a medicinal composition with the disulfamide phenothiazine compound with the structure of the formula I as an active and effective component and application of the disulfamide phenothiazine compound to preventing or treating diseases related to arginine vasopressin V1a receptors, arginine vasopressin V1b receptors, arginine vasopressin V2 receptors, a sympathetic nervous system or a renin-angiotensin-aldosterone system.

The medicine composition consists of one of AT1 receptor antagonist, its active metabolism product, ester and salt in treating effective amount of 4-800 mg, one or several kinds one B family vitamins in treating effective amount of 0.1-50 mg, and pharmaceutically acceptable carrier. The medicine composition of the present invention has the beneficial effects of raising the treating effect of blood pressure lowering AT1 receptor antagonist, strengthening the protecting effect of blood pressure lowering AT1 receptor antagonist on target organ and reducing the incidence rate of hemorrhage of the ocular fundus, angina pectoris, myocardial infarction and other complications.

The present invention discloses a medicine composition. Said medicine composition includes 4-600 mg of one of angiotensin II receptor antagonist and its active metabolic product, salts or esters, 100-1200 mg one of phenoxy acid compound and its active metabolic product, salts or esters and pharmaceutically-acceptable carrier. Said invention also provides the application of said medicine composition in preparation of medicine for preventing, curing and delaying hypertension and / or hyperlipemia and angiocardiopathy and cerbrovascular diseases due to hypertension or / and hyperlipemia.

The invention relates to N-substituted benzenesulfonyl phenothiazine compounds as well as a preparation method and application thereof, and particularly relates to N-substituted benzenesulfonyl phenothiazine compounds having a structure shown in a formula I described in the specification as well as a preparation method thereof, pharmaceutical compositions taking the N-substituted benzenesulfonyl phenothiazine compounds with a structure as shown in the formula I as active ingredients and use of the pharmaceutical compositions for preventing or treating diseases associated with an arginine vasopressin V1a receptor, an arginine vasopressin V1b receptor, an arginine vasopressin V2 receptor, a sympathetic nervous system or a rennin-angiotensin-aldosterone system.